Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 15;68(5):495-501.
doi: 10.1097/QAI.0000000000000529.

Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals

Jose R Castillo-Mancilla  1 , Amie Meditz, Cara Wilson, Jia-Hua Zheng, Brent E Palmer, Eric J Lee, Edward M Gardner, Sharon Seifert, Becky Kerr, Lane R Bushman, Samantha MaWhinney, Peter L Anderson
Affiliations

Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals

Jose R Castillo-Mancilla et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Elevated immune activation is associated with an increased risk of HIV acquisition. Tenofovir (TFV) has immunomodulatory properties in vitro, but how this extends in vivo remains unknown.

Methods: HIV-negative adults received daily coformulated TFV disoproxil fumarate 300 mg/emtricitabine (FTC) 200 mg for 30 days followed by a 30-day washout. Markers of T-cell activation, inflammation, and cytokines were measured before drug and on days 30 (on drug) and 60 (30-day washout). Data were analyzed using one-way analysis of variance/pairwise comparisons. Intracellular disposition of TFV-diphosphate and FTC-triphosphate in CD4 and CD8 T-cells and monocytes was characterized, and the relationship with immune activation was evaluated using Pearson's correlation coefficient.

Results: T-cell activation was available in 19 participants. CD38/HLA-DR coexpression on CD8 T-cells decreased from baseline to day 30 (3.97% vs. 2.71%; P = 0.03) and day 60 (3.97% vs. 2.41%; P = 0.008). Soluble CD27 decreased from baseline to day 60 (184.1 vs. 168.4 pg/mL; P = 0.001). Cytokines and inflammation markers were not significantly different. TFV-diphosphate and FTC-triphosphate were approximately 4-fold higher in monocytes vs. CD4 and CD8 T-cells but neither correlated with activation markers.

Conclusions: TFV disoproxil fumarate/FTC therapy was associated with decreased T-cell activation in HIV-negative adults, which could contribute to the antiviral effect of pre-exposure prophylaxis (NCT01040091; www.clinicaltrials.gov).

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest (see separate forms):

Dr. Anderson reports donation of study drug from Gilead Sciences during the conduct of the study and Contract work with Gilead Sciences. All others authors: no conflict of interest.

Figures

Figure 1
Figure 1
CD8+ T-cell (Panel A) and CD4+ T-cell (Panel B) immune activation (CD38/HLA-DR co-expression) at baseline (before drug), day 30 (after 30 days of TDF/FTC) and day 60 (30 days of washout). CD8+ T-cell ANOVA P=0.02. CD4+ T-cell ANOVA P=0.25. Bars and error bars represent geometric means and 95% confidence intervals, respectively. Statistical tests were conducted on loge transformed data. Abbreviations: TDF/FTC, tenofovir-disoproxil-fumarate/emtricitabine.
Figure 2
Figure 2
Plasma sCD27 (Panel A) and plasma sCD14 (Panel B) concentrations at baseline (before drug), day 30 (after 30 days of TDF/FTC) and day 60 (30 days of drug washout. sCD27 ANOVA P=0.001. sCD14 ANOVA P=0.06. Bars and error bars represent geometric means and 95% confidence intervals, respectively. Statistical tests were conducted on loge transformed data. Abbreviations: TDF/FTC, tenofovir-disoproxil-fumarate/emtricitabine; sCD27 plasma soluble CD27; sCD14, plasma soluble CD14.
See this image and copyright information in PMC

References

    1. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859–870. - PubMed
    1. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–1888. - PubMed
    1. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942–947. - PubMed
    1. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009;458:1034–1038. - PMC - PubMed
    1. Lu W, Chen S, Lai C, et al. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell rep. 2012;2:1736–1746. - PubMed

Publication types

Associated data